DBV Technologies : DBV Technologies' Extraordinary General Assembly on September 21, 2015
(Thomson Reuters ONE) -
Regulated Information
Bagneux, France, August 31, 2015
DBV Technologies' Extraordinary General Assembly on September 21, 2015
DBV Technologies (Euronext: DBV- ISIN: FR0010417345- NASDAQ: DBVT) a
biopharmaceutical company, announces that it will hold its Extraordinary General
Assembly on September 21, 2015 at 8:45 a.m. at the Company's headquarters,
80/ 84 rue des Meuniers, Green Square BAT A - 92220 Bagneux.
The notice containing the agenda and unique resolution was published in the
French Legal Journal ("BALO") on August 17(th), 2015 and the notice stating the
time and place of the meeting will be published according to French rules and
distribution requirements on September 4(th), 2015.
The preparatory documents for the Assembly (as listed in the French Commercial
Code) are posted on the DBV's website in the Investor Relations section:
http://www.dbv-technologies.com/en/investor-relations/general-meeting.
The preparatory documents for the Assembly will also be made available to
shareholders as of the convening of the meeting. Thus, in accordance with
applicable regulatory provisions:
* All registered shareholders may, until 5 days (included) before the
Assembly, request that the Company send them these documents, at their
express request by electronic means. For holders of bearer shares, the
exercise of this right is subject to the provision of a certificate of
participation in the bearer share accounts held by the authorized
intermediary;
* Any shareholder may consult the documents referred to in Articles L.
225-115 and R. 225-83 of the French Commercial Code at the Company's
headquarters.
About DBV Technologies
DBV Technologies is opening up a decisive new approach to the treatment of
allergies, a major public health problem in constant progression. The Company,
founded in 2002, has developed a unique proprietary technology, Viaskin®,
patented worldwide, for administering an allergen to intact skin without a
massive transfer to the blood stream, thereby significantly minimizing the risk
of allergic reaction in case of accidental exposure to the allergen.
The shares of DBV Technologies are traded on the B compartment of Euronext Paris
(stock symbol: DBV, ISIN code: FR0010417345) and on the Nasdaq in the form of
ADS (American Depositary Shares), each representing half of an ordinary share
(stock symbol: DBVT).
For more information on DBV Technologies, visit our website: www.dbv-
technologies.com.
Disclaimer
This press release contains forward-looking statements, including statements
about the potential safety and efficacy of Epicutaneous Immunotherapy (EPIT) via
Viaskin® Peanut and the regulatory pathway afforded by Breakthrough Therapy
designation by the U.S. Food and Drug Administration, which does not change the
standards for approval and is not a guarantee of success. These forward-looking
statements are not promises or guarantees and involve substantial risks and
uncertainties. The Company's product candidates have not been approved for sale
in any jurisdiction. Among the factors that could cause actual results to
differ materially from those described or projected herein are uncertainties
associated generally with research and development, clinical trials and related
regulatory reviews and approvals, the risk that historical preclinical results
may not be predictive of future clinical trial results, and the risk that
historical clinical trial results may not be predictive of future trial
results. A further list and description of these risks, uncertainties and other
risks can be found in the Company's regulatory filings with the French Autorité
des Marchés Financiers, the Company's Securities and Exchange Commission filings
and reports, including in the Company's Annual Report on Form 20-F for the year
ended December 31, 2014, and future filings and reports by the Company.
Existing and prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date hereof. DBV
Technologies undertakes no obligation to update or revise the information
contained in this Press Release, whether as a result of new information, future
events or circumstances or otherwise.
DBV Technologies Contact
Nathalie Donne
Director of Corporate Communication & Business Development
Tel.: +33(0)1 55 42 78 72
nathalie.donne(at)dbv-technologies.com
Media Contact
ALIZE RP
Press Relations
Caroline Carmagnol
Tel.: +33(0)6 64 18 99 59
caroline(at)alizerp.com
AGE 210915:
http://hugin.info/156437/R/1949016/708153.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
[HUG#1949016]
Unternehmensinformation / Kurzprofil:
Datum: 01.09.2015 - 14:12 Uhr
Sprache: Deutsch
News-ID 417322
Anzahl Zeichen: 5898
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 145 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies : DBV Technologies' Extraordinary General Assembly on September 21, 2015"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
